Compare Abeona Therapeutics Inc (ABEO) vs Global X Cybersecurity (BUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global X Cybersecurity — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Global X Cybersecurity trades at $39.45. Which is the better fit depends on your goals.
| ABEO | BUG | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $40.67 |
52-Week Low | $4.17 | $23.30 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BUG trades at $40.67, up 3.41% today, with a bullish technical trend supported by moving averages but overbought RSI levels. The cybersecurity ETF benefits from sector tailwinds as global spending exceeds $300 billion in 2026 (24/7 Wall Street, 2026-07-03), though AI disruption poses challenges. Key support lies at $39, with resistance at $41.
Outlook is mixed: strong sector growth supports upside, but premium valuations and AI-driven competitive threats present risks. Investors should weigh robust cybersecurity demand against potential earnings compression from rapid technological shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →
